Clinical trial
A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With…
NCT00437502 · Michael Morse, MD, Other · Completed
Key facts
| NCT number | NCT00437502 |
|---|---|
| Title | A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer |
| Official title | A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA-51) as Consolidation Following Optimal Debulking and Systemic Chemotherapy for Women With Advanced Stage Ovarian, Tubal, or Peritoneal Cancer |
| Lead sponsor | Michael Morse, MD, Other |
| Collaborators | Immunotope Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Epithelial Ovarian, Tubal or Peritoneal Cancer |
| Intervention type | Biological |
| Interventions | tumor peptide vaccine |
| Enrollment | 8 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Feb 21, 2007 |
| Last update posted | Nov 19, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: